BR112014007717A2 - composições e métodos para teste de toxicidade - Google Patents

composições e métodos para teste de toxicidade

Info

Publication number
BR112014007717A2
BR112014007717A2 BR112014007717A BR112014007717A BR112014007717A2 BR 112014007717 A2 BR112014007717 A2 BR 112014007717A2 BR 112014007717 A BR112014007717 A BR 112014007717A BR 112014007717 A BR112014007717 A BR 112014007717A BR 112014007717 A2 BR112014007717 A2 BR 112014007717A2
Authority
BR
Brazil
Prior art keywords
methods
toxicity testing
compositions
testing compositions
analysis
Prior art date
Application number
BR112014007717A
Other languages
English (en)
Other versions
BR112014007717B1 (pt
Inventor
Arthur Johnson Eric
Clare Meyer Whitemarsh Regina
Pellett Sabine
Howard Tepp William
Original Assignee
Cellsnap Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellsnap Llc filed Critical Cellsnap Llc
Publication of BR112014007717A2 publication Critical patent/BR112014007717A2/pt
Publication of BR112014007717B1 publication Critical patent/BR112014007717B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo composições e métodos para teste de toxicidade a presente invenção refere-se a composições e métodos para os agentes de teste (por exemplo, detecção e análise de neurotoxina do clostridium botulinum (ntb)). em particular, a presente invenção refere-se à utilização de células derivadas de células-tronco pluripotentes humanas induzidas (hips) para detecção e análise de agente.
BR112014007717-7A 2011-09-29 2012-09-28 Métodos in vitro de testar uma neurotoxina de clostridium botulinum (ntb) para a atividade e uso de uma célula neuronal derivada de célula-tronco pluripotente humana induzida (hips) BR112014007717B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161540693P 2011-09-29 2011-09-29
US61/540,693 2011-09-29
PCT/US2012/057825 WO2013049508A1 (en) 2011-09-29 2012-09-28 Compositions and methods for toxigenicity testing

Publications (2)

Publication Number Publication Date
BR112014007717A2 true BR112014007717A2 (pt) 2017-04-25
BR112014007717B1 BR112014007717B1 (pt) 2021-07-20

Family

ID=47996425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007717-7A BR112014007717B1 (pt) 2011-09-29 2012-09-28 Métodos in vitro de testar uma neurotoxina de clostridium botulinum (ntb) para a atividade e uso de uma célula neuronal derivada de célula-tronco pluripotente humana induzida (hips)

Country Status (20)

Country Link
US (1) US9217172B2 (pt)
EP (1) EP2761065B1 (pt)
JP (1) JP5877617B2 (pt)
KR (1) KR101640694B1 (pt)
CN (1) CN103958747B (pt)
AU (1) AU2012315783B2 (pt)
BR (1) BR112014007717B1 (pt)
CA (1) CA2850531C (pt)
ES (1) ES2653249T3 (pt)
HK (1) HK1199911A1 (pt)
HR (1) HRP20171937T1 (pt)
HU (1) HUE037509T2 (pt)
IL (1) IL231768B (pt)
LT (1) LT2761065T (pt)
MX (1) MX348188B (pt)
PL (1) PL2761065T3 (pt)
RU (1) RU2616281C2 (pt)
SG (1) SG11201401007SA (pt)
SI (1) SI2761065T1 (pt)
WO (1) WO2013049508A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339790B (zh) 2013-06-28 2018-04-17 莫茨制药有限及两合公司 用于确定神经毒素多肽在细胞中的生物活性的工具和方法
WO2015021433A1 (en) 2013-08-09 2015-02-12 Biomadison, Inc. Botulinum toxin assay with improved sensitivity
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
CA3010146A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
KR102423739B1 (ko) 2016-05-27 2022-07-21 입센 바이오팜 리미티드 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
US10751394B2 (en) * 2016-10-25 2020-08-25 Cellsnap Llc Neurotoxins and uses thereof
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
KR20190126794A (ko) 2017-03-24 2019-11-12 메르츠 파마 게엠베하 운트 코. 카가아 타액과다증의 치료에서의 보툴리늄 신경독소의 개선된 용도
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
EP3700919A1 (en) 2017-10-26 2020-09-02 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US20200354706A1 (en) 2017-11-22 2020-11-12 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2020070017A1 (en) 2018-10-02 2020-04-09 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for treating lipoedema
EP3863589A1 (en) 2018-10-08 2021-08-18 Merz Pharma GmbH & Co. KGaA Neurotoxin prefilled vial
WO2020169578A1 (en) 2019-02-21 2020-08-27 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
KR102297991B1 (ko) * 2019-10-11 2021-09-07 주식회사 하울바이오 SNARE 복합체를 억제하는 항-Syntaxin 1A 항체 및 이의 용도
BR112022023413A2 (pt) 2020-06-05 2022-12-20 Merz Pharma Gmbh & Co Kgaa Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume
CN113774023B (zh) * 2021-09-28 2022-11-25 中国食品药品检定研究院 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途
TW202333767A (zh) 2022-01-14 2023-09-01 英商益普生生物製藥有限公司 中度至極重度眉間紋及眼角外紋之治療
WO2023156389A1 (en) 2022-02-15 2023-08-24 Merz Pharma Gmbh & Co. Kgaa Liquid botulinum toxin formulation and use thereof
AR128515A1 (es) 2022-02-15 2024-05-15 Merz Pharma Gmbh & Co Kgaa Formulación de toxina botulínica líquida y su uso
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法
WO2024115413A1 (en) 2022-11-28 2024-06-06 Merz Pharma Gmbh & Co. Kgaa High concentration botulinum toxin treatment for neck rejuvenation
WO2024115412A1 (en) 2022-11-28 2024-06-06 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin injection in platysma for lower face and neck rejuvenation
WO2024126649A1 (en) 2022-12-15 2024-06-20 Merz Pharma Gmbh & Co. Kgaa Injectable gel comprising botulinum toxin and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
EP1595951A1 (en) * 1997-07-21 2005-11-16 Arpi Matossian-Rogers Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies
US7115399B2 (en) 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US6984375B2 (en) 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
GB2398636A (en) 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
US8137924B2 (en) 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
WO2005082096A2 (en) * 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
GB2416849A (en) 2004-08-04 2006-02-08 Ipsen Ltd Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
CA2610103A1 (en) 2005-09-19 2007-03-19 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US8949033B2 (en) 2006-04-28 2015-02-03 The Chemo-Sero-Therapeutic Research Institute Method for quantification of neurotoxin
US8067192B2 (en) * 2007-06-05 2011-11-29 City Of Hope Methods for detection of botulinum neurotoxin
CA2708780A1 (en) * 2007-12-11 2009-06-18 Research Development Foundation Small molecules for neuronal differentiation of embryonic stem cells
WO2009098698A2 (en) * 2008-02-07 2009-08-13 Shahar Cohen Compartmental extract compositions for tissue engineering
ES2524312T3 (es) 2008-03-14 2014-12-05 Allergan, Inc. Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica
WO2010008486A2 (en) * 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
EP2191847A1 (en) * 2008-11-19 2010-06-02 Merz Pharma GmbH & Co.KGaA Method for preparing compositions comprising a protein, water and glycerol
EP2398897B1 (en) * 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CA2753679C (en) * 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
KR102017327B1 (ko) 2009-03-13 2019-09-03 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US9506114B2 (en) 2009-08-28 2016-11-29 Cellular Dynamics International, Inc. Identifying genetic variation in affected tissues
JP5898086B2 (ja) 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
US9096886B2 (en) 2011-03-11 2015-08-04 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
WO2012135621A2 (en) 2011-03-30 2012-10-04 Cellular Dynamics International. Inc Priming of pluripotent stem cells for neural differentiation
WO2013102088A2 (en) * 2011-12-31 2013-07-04 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
JP2015509372A (ja) * 2012-03-07 2015-03-30 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 修飾ルシフェラーゼに基づいて神経毒活性を測定するための手段および方法
US8778623B2 (en) * 2012-09-14 2014-07-15 Wisconsin Alumni Research Foundation Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin
US9102901B2 (en) * 2012-12-20 2015-08-11 Rohm And Haas Electronic Materials Llc Methods and compositions for removal of metal hardmasks

Also Published As

Publication number Publication date
EP2761065B1 (en) 2017-12-06
RU2616281C2 (ru) 2017-04-13
SG11201401007SA (en) 2014-04-28
EP2761065A4 (en) 2015-05-06
IL231768A0 (en) 2014-05-28
PL2761065T3 (pl) 2018-02-28
CN103958747B (zh) 2017-03-01
BR112014007717B1 (pt) 2021-07-20
HUE037509T2 (hu) 2018-09-28
KR101640694B1 (ko) 2016-07-18
LT2761065T (lt) 2018-01-10
MX2014003874A (es) 2014-08-18
US9217172B2 (en) 2015-12-22
WO2013049508A1 (en) 2013-04-04
CA2850531C (en) 2016-06-07
KR20140086981A (ko) 2014-07-08
CN103958747A (zh) 2014-07-30
HK1199911A1 (en) 2015-07-24
EP2761065A1 (en) 2014-08-06
MX348188B (es) 2017-06-01
HRP20171937T1 (hr) 2018-02-09
US20140234857A1 (en) 2014-08-21
RU2014117161A (ru) 2015-11-10
SI2761065T1 (en) 2018-02-28
IL231768B (en) 2019-06-30
ES2653249T3 (es) 2018-02-06
CA2850531A1 (en) 2013-04-04
AU2012315783B2 (en) 2015-08-20
AU2012315783A1 (en) 2014-04-17
JP2014528724A (ja) 2014-10-30
JP5877617B2 (ja) 2016-03-08

Similar Documents

Publication Publication Date Title
BR112014007717A2 (pt) composições e métodos para teste de toxicidade
AR118722A2 (es) Proteínas tóxicas para especies de insectos hemípteros
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
PE20181131A1 (es) COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
IN2014DN09678A (pt)
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
BR112013021590A2 (pt) detecção de capacitância em ensaio eletroquímico com resposta otimizada
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
GB201207297D0 (en) Analytical methods and arrays for use in the same
CR20130657A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
BR112017019841A2 (pt) técnica de análise de amostra de tecido
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BR112013008749A2 (pt) análogos de ciclosporina
NZ592994A (en) Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene
WO2014124307A3 (en) Targeted theranostics
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CELLSNAP, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2012, OBSERVADAS AS CONDICOES LEGAIS.